drugset / Trial / NCT05156541

Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts

NCT05156541

Phase 3 Completed 30 enrolled SPP Pharmaclon Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the effectiveness of destructive therapy for anogenital warts in combination with the use of Ingaron in comparison with destructive therapy.

Timeline

Start
2009-05-18
Primary completion
2010-06-30
Completion
2010-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject interferon gamma Protein / enzyme biologic 100000 iu